Kapitel
Lizenziert
Nicht lizenziert
Erfordert eine Authentifizierung
List of Illustrations
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Kapitel in diesem Buch
- Frontmatter i
- Contents vii
- List of Illustrations ix
- List of Tables xi
- Acknowledgments xiii
- List of Abbreviations and Acronyms xvii
- Introduction. The Gatekeeper 1
- Chapter One. Reputation and Regulatory Power 33
-
Part One: Organizational Empowerment and Challenge
- Chapter Two. Reputation and Gatekeeping Authority: The Federal Food, Drug and Cosmetic Act of 1938 and Its Aftermath 73
- Chapter Three. The Ambiguous Emergence of American Pharmaceutical Regulation, 1944–1961 118
- Chapter Four. Reputation and Power Crystallized: Thalidomide, Frances Kelsey, and Phased Experiment, 1961–1966 228
- Chapter Five. Reputation and Power Institutionalized: Scientific Networks, Congressional Hearings, and Judicial Affirmation, 1963–1986 298
- Chapter Six. Reputation and Power Contested: Emboldened Audiences in Cancer and Aids, 1977–1992 393
-
Part Two: Pharmaceutical Regulation and Its Audiences
- Chapter Seven. Reputation and the Organizational Politics of New Drug Review 465
- Chapter Eight. The Governance of Research and Development: Gatekeeping Power, Conceptual Guidance, and Regulation by Satellite 544
- Chapter Nine. The Other Side of the Gate: Reputation, Power, and Post-Market Regulation 585
- Chapter Ten. The Détente of Firm and Regulator 635
- Chapter Eleven. American Pharmaceutical Regulation in International Context: Audiences, Comparisons, and Dependencies 686
- Chapter Twelve. Conclusion: A Reputation in Relief 727
- Primary Sources and Archival Collections 753
- Index 759
Kapitel in diesem Buch
- Frontmatter i
- Contents vii
- List of Illustrations ix
- List of Tables xi
- Acknowledgments xiii
- List of Abbreviations and Acronyms xvii
- Introduction. The Gatekeeper 1
- Chapter One. Reputation and Regulatory Power 33
-
Part One: Organizational Empowerment and Challenge
- Chapter Two. Reputation and Gatekeeping Authority: The Federal Food, Drug and Cosmetic Act of 1938 and Its Aftermath 73
- Chapter Three. The Ambiguous Emergence of American Pharmaceutical Regulation, 1944–1961 118
- Chapter Four. Reputation and Power Crystallized: Thalidomide, Frances Kelsey, and Phased Experiment, 1961–1966 228
- Chapter Five. Reputation and Power Institutionalized: Scientific Networks, Congressional Hearings, and Judicial Affirmation, 1963–1986 298
- Chapter Six. Reputation and Power Contested: Emboldened Audiences in Cancer and Aids, 1977–1992 393
-
Part Two: Pharmaceutical Regulation and Its Audiences
- Chapter Seven. Reputation and the Organizational Politics of New Drug Review 465
- Chapter Eight. The Governance of Research and Development: Gatekeeping Power, Conceptual Guidance, and Regulation by Satellite 544
- Chapter Nine. The Other Side of the Gate: Reputation, Power, and Post-Market Regulation 585
- Chapter Ten. The Détente of Firm and Regulator 635
- Chapter Eleven. American Pharmaceutical Regulation in International Context: Audiences, Comparisons, and Dependencies 686
- Chapter Twelve. Conclusion: A Reputation in Relief 727
- Primary Sources and Archival Collections 753
- Index 759